moxifloxacin intravenous / Generic mfg. - LARVOL DELTA

TEN-YEAR EXPERIENCE OF PERITONEAL DIALYSIS–RELATED INFECTIONS CAUSED BY NON-TUBERCULOUS MYCOBACTERIA: A SINGLE-CENTER RETROSPECTIVE OBSERVATIONAL STUDY (ISN-WCN 2026) - "Antibiotic therapies, primarily moxifloxacin, clarithromycin, and amikacin, were administered in all cases. Therefore, routine and repeated acid-fast bacilli testing is essential for the appropriate diagnosis of PD-related infections caused by NTM. Further research is warranted to establish standardized strategies for the diagnosis and management of NTM-related PD infections."

Nontuberculous mycobacteria • Observational data • Retrospective data • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases

MANAGING FULMINANT LIVER FAILURE FROM ANTI-TUBERCULOSIS DRUG-INDUCED HEPATOTOXICITY USING DPMAS: A CASE REPORT (ISN-WCN 2026) - "Moxifloxacin and ethambutol were retained, while other agents were tapered or reintroduced cautiously as liver function improved...Early recognition of hepatic injury, prompt withdrawal of offending agents, and timely initiation of DPMAS can significantly improve outcomes. This case exemplifies the potential of extracorporeal liver support systems to bridge patients to recovery and redefine management strategies for drug-induced hepatic failure in developing healthcare settings."

Case report • Clinical • Cardiovascular • CNS Disorders • Epilepsy • Heart Failure • Hematological Disorders • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Failure • Nephrology • Pruritus • Respiratory Diseases • Thrombocytosis • Thrombosis • Tuberculosis

Key findings from the 2024 Mycoplasma genitalium Antimicrobial Resistance Surveillance (MARS) programme. (PubMed, Int J STD AIDS) - "Compared to MARS 2023, high levels of macrolide resistance remain, with increasing fluoroquinolone (p = 0.008) and dual resistance (p = 0.024).Most individuals (87.3%) were prescribed the recommended first- or second-line treatments and 80.8% received doxycycline as a pre-treatment. Resistant genotypes were common among those with a positive test-of-cure (TOC): 90.9% of individuals with a positive TOC following azithromycin were infected with a macrolide-resistant strain, and 51.6% of those with a positive TOC following moxifloxacin were infected with a fluoroquinolone-resistant strain. However, genotype did not consistently predict TOC outcome, as 14.6% of those with negative TOCs following azithromycin had macrolide-resistant infections and 16.6% of those with negative TOCs following moxifloxacin had fluoroquinolone-resistant infections.ConclusionsMARS 2024 is the largest dataset examining antimicrobial resistance in M. genitalium in England, confirming widespread..."

Journal • Infectious Disease

Effectiveness and safety of bedaquiline, pretomanid, linezolid and moxifloxacin in drug-resistant tuberculosis patients in selected public hospitals in Ethiopia: a multicenter retrospective cohort study. (PubMed, BMC Infect Dis) - No abstract available

Journal • Retrospective data • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Nitrogen-doped carbon dot-based dual-emission ratiometric probe for smartphone-assisted ultrasensitive detection of moxifloxacin. (PubMed, Sci Rep) - No abstract available

Journal

In vitro activity of delafloxacin vs ciprofloxacin, levofloxacin and moxifloxacin against MRSA (ESCMID Global 2026) - No abstract available

Preclinical

The paradox of gyrB E501D: salvaging levofloxacin options by deciphering the phenotypic dissociation between moxifloxacin and levofloxacin (ESCMID Global 2026) - No abstract available

Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Increased risk of hyperbilirubinemia with a four-month rifapentine/moxifloxacin regimen in elderly patients with drug-susceptible pulmonary tuberculosis: a multi-centre prospective study in Taiwan (ESCMID Global 2026) - No abstract available

Clinical • Hepatology • Infectious Disease • Respiratory Diseases • Tuberculosis

Results from RML TB trial: phase IIb multi-centre, randomised, open clinical trial in people with drug susceptible pulmonary tuberculosis using optimised dose rifampicin, optimised dose moxifloxacin and linezolid (ESCMID Global 2026) - No abstract available

Clinical • P2b data • Infectious Disease • Respiratory Diseases • Tuberculosis

The triggered antioxidant response and corresponding metabolomics expression of Caenorhabditis elegans for chronic exposure to moxifloxacin and trace copper. (PubMed, Bioresour Bioprocess) - "Meanwhile, at the exposure to MOX-Cu, the levels of ROS and lipofuscin were decreased due to the up-regulation of sod-1 and daf-16, and the antioxidant defense was promoted and confirmed by the increase of amino acids and their related metabolic pathways. These results can provide a theoretical basis for the toxicity evaluation of typical antibiotics (MOX) that co-existing with trace heavy metals in natural environment media and bioresources processes."

Journal • SOD3

Evaluating treatment outcomes stratified by regimen among drug-resistant TB patients in Sierra Leone. (PubMed, Public Health Action) - "Under routine programmatic conditions in Sierra Leone, BPaL/BPaLM achieved higher treatment success than standardised short or individualised long regimens. However, HIV co-infection and undernutrition predicted poorer outcomes, underscoring the need for integrated nutritional support, expanded drug-susceptibility testing, and strengthened TB/HIV services."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open

Therapeutic Penetrating Keratoplasty for Aspergillus Fungal Keratitis: A Case Report. (PubMed, Cureus) - "Prior to referral, he had been hospitalized at a tertiary center and treated with topical moxifloxacin and fluconazole without clinical improvement...Cultures demonstrated Aspergillus lentulus sensitive to voriconazole...TPK with meticulous anterior chamber lavage provided a definitive cure for fungal keratitis refractory to topical and systemic therapy. Postoperative administration of cyclosporine A instead of corticosteroids appears to be a safe and effective alternative for graft preservation after TPK for fungal keratitis."

Journal • Infectious Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Transplantation

Moxifloxacin-Induced Peripheral Neuropathy: A Rare Side Effect of Fluoroquinolone Therapy in Tuberculosis Management. (PubMed, Cureus) - "While FDA warnings emphasize the often-rapid onset of fluoroquinolone-associated nerve damage within days of initiation, this case illustrates a delayed, cumulative toxicity profile that aligns with recent epidemiological evidence. As global TB guidelines shift toward four-month MXF regimens, this report highlights a critical safety consideration for clinicians and the importance of routine neurological screening throughout the entire treatment course to detect early signs of toxicity and prevent the development of potentially permanent PN."

Adverse events • Journal • Infectious Disease • Pain • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Lefamulin versus omadacycline for community acquired bacterial pneumonia: a systematic review and anchored indirect treatment comparison using moxifloxacin as the common comparator. (PubMed, J Comp Eff Res) - "These findings highlight the need to further accumulate additional clinical data or real-world evidence to support future comparative research. The introduction of novel antibiotics, such as LEF and OMA, represents an important step toward addressing the pressing challenge of antimicrobial resistance and improving outcomes for patients with CABP in China."

Journal • Review • Infectious Disease • Influenza • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Phase classification: P4 ➔ P3 | N=7100 ➔ 10000 | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=6800 | Recruiting | Sponsor: MJM Bonten | N=4000 ➔ 6800 | Trial completion date: Feb 2019 ➔ Jun 2022 | Trial primary completion date: Feb 2019 ➔ Dec 2021 | Initiation date: Dec 2015 ➔ Apr 2016

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=7100 | Recruiting | Sponsor: MJM Bonten | Trial completion date: Jun 2022 ➔ Dec 2023

Trial completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=4000 | Recruiting | Sponsor: UMC Utrecht

New P4 trial • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Trial completion date: Dec 2025 ➔ Feb 2028 | Trial primary completion date: Dec 2023 ➔ Feb 2026

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=20000 | Recruiting | Sponsor: UMC Utrecht | N=10000 ➔ 20000

Enrollment change • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Distribution and Antibiotic Resistance Trends of Staphylococcus aureus: A 10-Year Retrospective Study. (PubMed, Microb Drug Resist) - "In conclusion, the prevalence of S. aureus infections within our hospital remains a significant concern. It is imperative to closely monitor the epidemiological distribution and ABR patterns of this pathogen to facilitate early intervention and guide appropriate therapeutic strategies."

Journal • Retrospective data • Infectious Disease • Musculoskeletal Diseases • Orthopedics • Pediatrics

Empirical antibiotic use, resistance patterns, and their impact on clinical outcomes in a Yemeni tertiary hospital. (PubMed, New Microbes New Infect) - "The most commonly prescribed antibiotics were Ceftriaxone, Vancomycin, Levofloxacin, Meropenem, Imipenem/Cilastatin, and Metronidazole. Significant resistance (>50%) was observed against Moxifloxacin, Clindamycin, and all tested beta-lactam agents except Cefuroxime (42%)...These findings underscore the need for effective interventions to optimize antibiotic use and mitigate the growing threat of resistance in Yemen. Strategies such as enhanced diagnostic capabilities, improved stewardship programs, and rational prescribing practices are essential to improve patient outcomes and preserve the effectiveness of antibiotics."

Clinical data • Journal

Nontuberculous Mycobacterial Disease After Lung Transplantation in a Former TNF-α Inhibitor User (ISHLT 2026) - "Notably, the patient had been on etanercept therapy from 2018 until transplantation...Combination therapy with azithromycin, ethambutol, rifabutin, and amikacin was initiated; amikacin was promptly discontinued due to nephrotoxicity and replaced with moxifloxacin. The latest MRI shows progression of bone inflammation and destruction despite ongoing therapy. Extreme elevation of serum amyloid A (692 mg/L) along with GFR decline and malnutrition, despite nutritional support, is very likely secondary to AA amyloidosis.Summary Complete microbiological and molecular workup, including PCR for TB and NTM, is warranted in all granulomatous lesions and in any chronic, culture-negative wound."

Nontuberculous mycobacteria • Amyloidosis • Back Pain • Immunology • Infectious Disease • Inflammation • Musculoskeletal Diseases • Musculoskeletal Pain • Nontuberculous Mycobacterial Disease • Orthopedics • Pulmonary Disease • Respiratory Diseases • Transplantation • CRP

Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort. (PubMed, BMJ Open) - "This cross-sectional study will consist of 100 Namibian participants with matched human DNA and PK data of MDR-TB cases receiving isoniazid, clofazimine, bedaquiline and the fluoroquinolones (levofloxacin or moxifloxacin). N21/11/136) and the University of Cape Town Human Research Ethics Committee (Ref. 500/2022)."

Biomarker • Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis